SavedAdd your journal

Journals / Molecular Imaging and Radionuclide Therapy / 2019 / Cilt: 28 - Sayı: 1

The Role of Pre-ablative Stimulated Thyroglobulin and Thyroglobulin/ Thyroid-Stimulating Hormone Ratio for Predicting Metastasis in Thyroid Cancer

Tiroid Kanserinde Pre-ablatif Stimüle Tiroglobulin ve Tiroglobulin/Tiroid Uyarıcı Hormon Oranının Metastaz Tahminindeki Rolü

Fikri Selçuk ŞİMŞEK
Fadime DEMİR
Tansel Ansal BALCI
Pages
21–26
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: There was a significant difference between group 3 and other groups (group 1 and group 2) in terms of Tg (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to investigate the predictive value of pre-ablative stimulated thyroglobulin (Tg) and Tg/thyroid-stimulating hormone (TSH) to identify lymph node metastasis (LNM) or distant metastases (DM) prior to radioactive iodine (RAI) treatment.
📊
Key Findings & Data:Methods: Patients without metastasis were included in group 1 (n=100), those with LNM were included in group 2 (n=83), and those with DM constituted group 3 (n=23).
💡
Conclusion & Impact:Results: There was a significant difference between group 3 and other groups (group 1 and group 2) in terms of Tg (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we aimed to investigate the predictive value of pre-ablative stimulated thyroglobulin (Tg) and Tg/thyroid-stimulating hormone (TSH) to identify lymph node metastasis (LNM) or distant metastases (DM) prior to radioactive iodine (RAI) treatment. Methods: Patients without metastasis were included in group 1 (n=100), those with LNM were included in group 2 (n=83), and those with DM constituted group 3 (n=23). Tg and TSH values were measured approximately 4 hours prior to RAI ablation therapy. Results: There was a significant difference between group 3 and other groups (group 1 and group 2) in terms of Tg (p

Özet

Amaç: Bu çalışmada, radyoaktif iyot (RAİ) tedavisi öncesi lenf nodu metastazını veya uzak metastazları belirlemek için pre-ablatif stimüle tiroglobulin (Tg) ve Tg/tiroid-uyarıcı hormonun (Tg/TSH) prediktif değerini araştırmayı amaçladık. Yöntem: Grup 1’e (n=100) metastaz saptanmayan hastalar, grup 2’ye (n=83) lenf nodu metastazı olan hastalar ve grup 3’e (n=23) uzak metastazı olan hastalar dahil edildi. Tg ve TSH değerleri RAİ tedavisinden yaklaşık 4 saat önce ölçüldü. Bulgular: Grup 3 ile diğer gruplar (grup 1 ve grup 2) arasında Tg (p

🔖

Cite This Article

ŞİMŞEK, F. S., DEMİR, F., BALCI, T. A. (2022). The Role of Pre-ablative Stimulated Thyroglobulin and Thyroglobulin/ Thyroid-Stimulating Hormone Ratio for Predicting Metastasis in Thyroid Cancer. Molecular Imaging and Radionuclide Therapy, Cilt: 28 - Sayı: 1, 21–26. https://ajindex.com/articles/581598

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-34.
  2. McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 2013;381:10461057. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United kingdom national multidisciplinary guidelines. Laryngol Otol 2016;130:S150-S160. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. J Clin Endocrinol Metab 2006;91:2892-2899.
  3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
  4. Amdur RJ, Dan T, Mazzaferri E. Absence of Bone Marrow Toxicity in Elderly Patients Treated With Recombinant Human Thyroidstimulating Hormone and Empirically Dosed Radioiodine for Thyroid Cancer. Am J Clin Oncol 2013;36:348-353.
  5. Tian JJ, Tao R, Shen YF, Xia SY, Li C. Correlation of serum thyroglobulin and anti-thyroglobulin antibody levels with pulmonary metastasis and bone metastasis in patients with thyroid cancer. Journal of Hainan Medical University 2017;23:101-104.
  6. Spencer CA, Lopresti JS, Fatemi S, Nicoloff JT. Detection of Residual and Recurrent Differentiated Thyroid Carcinoma by Serum Thyroglobulin Measurement. Thyroid 1999;9:435-441.
  7. Cao CJ, Dou CY, Lian J, Luan ZS, Zhou W, Xie W, Chen L, Zhou K, Lai H. Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis. Oncol Lett 2018;15:8141-8148.
  8. Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Jeong SY, Lee SW, Lee J, Ahn BC. Difference of Clinical and Radiological Characteristics According to Radioiodine Avidity in Pulmonary Metastases of Differentiated Thyroid Cancer. Nucl Med Mol Imaging 2014;48:5562. Qutbi M, Shafeie B, Amoui M, Tabeie F, Azizmohammadi Z, Mahmoud-Pashazadeh A, Javadi H, Assadi M, Asli IN. Evaluation of Prognostic Factors Associated With Differentiated Thyroid Carcinoma